Clinical Trials
277 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Lutécio
Instituto do Cancer do Estado de São Paulo
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
ARC-27
Arcus Biosciences, Inc.
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
Centre Antoine Lacassagne
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
LuCa-MERIT-1
BioNTech SE
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Wake Forest University Health Sciences
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co., Ltd.
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Gilead Sciences
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Prelude Therapeutics
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
I-FLOAT
University of Chicago
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
AbbVie
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.